AACR Annual Meeting 2025, Chicago, IL, April 25-30
Conference
genOway presentation

genOway’s program at the American Association for Cancer Research Annual Meeting 2025
🔬 Spotlight Theater presentation
Tuesday, April 29, 2025 | 3 pm - Spotlight Theater E
Title: "Assessment of translational tumor biology, and biologic's efficacy and safety in preclinical humanized models"
Presenter: Kader Thiam, CSO & SVP – Discovery, Preclinical Models & Services
Presentation highlights:
- genO-BRGSF-HIS mouse is a tool to assess the efficacy and safety of immunotherapies targeting lymphoid and myeloid cellsgenO-BRGSF-HIS mouse
- TME in genO-BRGSF-HIS mice is shaped by tumor type and tumor burden
- genO-hFcγR model represents an alternative to genO-BRGSF-HIS to evaluate compounds working through Fc-mediated functions
📰 Poster presentations
⮞ Tumor cell line-derived xenograft subtype shapes tumor microenvironment composition in genO-BRGSF-HIS mice | Download poster here
- Human CD47 and SIRPα expression patterns recapitulate the murine expression of CD47 and SIRPα in genO-hCD47/hSIRPα model
- Efficacy and safety of CD47- and/or SIRPα-targeting agents can be assessed in the genO-hCD47/hSIRPα model
- genO-hCD47/hSIRPα model is suitable for biodistribution assay for non-invasive in vivo imaging of tumors
⮞ Preclinical double-humanized genO-hCD47/hSIRPα mouse model and MC38 cell line expressing human CD47 for efficacy and safety assessment of anti-CD47/SIRPα-targeting therapies | Download poster here
- genO-BRGSF-HIS mouse is permissive to cell line xenograft engraftment
- TME composition and cell polarization evolve with tumor burden and depend on tumor type in genO-BRGSF-HIS mouse
- genO-BRGSF-HIS mouse model is a valuable tool to investigate mechanism of action of immunotherapies
⮞ Functional γδ T cells in genO-BRGSF-HIS mice | Download poster here
- γδ T cells develop in genO-BRGSF-HIS mice and can be expanded ex vivo and in vivo using Vγ9 expanders
- γδ T cells are recruited into the TME of tumor-bearing genO-BRGSF-HIS mice
- genO-BRGSF-HIS model brings a new perspective to evaluate therapies designed to expand and activate γδ T cells
⮞ genO-hCCR8/hCCL1 humanized model for efficacy assessment of CCR8/CCL1-targeting therapies | Download poster here
- Humanization of both CCR8 and CCL1 is required for a functional axis and does not alter immune cell distribution in genO-hCCR8/hCCL1 compared to WT mice
- CCR8-targeting therapies can be assessed in genO-hCCR8/hCCL1 model
- Human-like expression pattern of CCR8 in genO-BRGSF-HIS naïve Tregs makes it a more suitable model for safety and PD assessment
AACR Annual Meeting 2025, Chicago, IL, April 25-30
Get in touch
Other news & events
Scientific excellence
From model design to experimental results
Featured in 600+ scientific articles
Collaborative approach
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Robust validation data on catalog models
Generated with biopharma partners and in-house
Innovative technologies
and guaranteed freedom to operate
Easy access to models
Models with certified health status from professional breeders in US and Europe